Optimizing Outcomes and Addressing Adversities of Immunotherapy in Lung Cancer

  • 12k

    Total Downloads

  • 38k

    Total Views and Downloads

About this Research Topic

Submission closed

Background

Immunotherapy targeting immune checkpoints (e.g. PD-1/L1, CTLA-4, etc.) has revolutionized our management of various tumors, including lung cancer. However only a minority of lung cancer patients benefit directly from immunotherapy, and many of them may develop immune-related adverse effects (irAEs) that could further limit the therapeutic value of immunotherapy. Finding the right patient population, uncoupling the therapeutic response from irAEs, and broadening the application under various clinical settings are therefore urgently important - indeed, they represent therapeutic challenges and opportunities in lung cancer immunotherapy.

The goal of this collection is to address above-mentioned challenges and opportunities via the following research areas:
1) identify better predictive biomarkers;
2) enhance therapeutic response from immunotherapy;
3) early recognition and management of irAEs;
4) innovative approaches to uncouple therapeutic response and irAEs;
5) novel immune checkpoints and immunotherapeutic interventions, as well as novel therapeutic combinations;
6) use of immunotherapy under various clinical conditions.

We welcome both preclinical and clinical original research articles and reviews addressing the following (but not limited to the following) research topics:
- Early recognition and clinical management of irAEs. The mechanistic dissection of irAEs and the potential approach to uncouple irAEs from immunotherapy response
- The use of microbiome, extracellular vesicles, genomic/proteomic signatures to predict response and irAEs
- Enhancing immunotherapy response via targeting the tumor immune microenvironment, metabolic reprogramming of cancer and/or immune cells, cytokine signaling, combination of innate and adaptive immunity, using novel immune checkpoints, novel delivery of immune cells and/or therapeutic agents, as well as novel therapeutic approaches
- The use of immunotherapy in the neoadjuvant and adjuvant settings

COIs:
Dr. Jarushka Naidoo has had research funded by Merck, AstraZeneca, and Bristol Myers Squibb
Dr. Oscar Arrieta has had research funded by National Council for Science and Technology in Mexico (CONACyT), Pfizer, AstraZeneca, Boehringer Ingelheim, Lilly, Merck, Bristol-Myers Squibb, and Roche
Dr. Zhang has served as a scientific advisor/consultant for: AstraZeneca, Biodesix, Novocure, Bayer, Daiichi Sankyo, Mirati, Novartis, Cardinal Health, Bristol-Myers Squibb, Nexus Health and Sanofi. He is on the speakers’ bureau for AstraZeneca, Regeneron, Sanofi and MJH Life Sciences. Dr. Zhang has also received previous research funding from AstraZeneca, Biodesix, Novartis, Genentech/Roche, Mirati, AbbVie and Hengrui Therapeutics

Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.

Keywords: lung cancer, immunotherapy, immune-related adverse effects, irAEs, adversities, outcomes

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Frequently asked questions

  • Frontiers' Research Topics are collaborative hubs built around an emerging theme.Defined, managed, and led by renowned researchers, they bring communities together around a shared area of interest to stimulate collaboration and innovation.

    Unlike section journals, which serve established specialty communities, Research Topics are pioneer hubs, responding to the evolving scientific landscape and catering to new communities.

  • The goal of Frontiers' publishing program is to empower research communities to actively steer the course of scientific publishing. Our program was implemented as a three-part unit with fixed field journals, flexible specialty sections, and dynamically emerging Research Topics, connecting communities of different sizes and maturity.

    Research Topics originate from the scientific community. Many of our Research Topics are suggested by existing editorial board members who have identified critical challenges or areas of interest in their field.

  • As an editor, Research Topics will help you build your journal, as well as your community, around emerging, cutting-edge research. As research trailblazers, Research Topics attract high-quality submissions from leading experts all over the world.

    A thriving Research Topic can potentially evolve into a new specialty section if there is sustained interest and a growing community around it.

  • Each Research Topic must be approved by the specialty chief editor, and they fall under the editorial oversight of our editorial boards, supported by our in-house research integrity team. The same standards and rigorous peer review processes apply to articles published as part of a Research Topic as for any other article we publish.

      In 2023, 80% of the Research Topics we published were edited or co-edited by our editorial board members, who are already familiar with their journal's scope, ethos, and publishing model. All other topics are guest edited by leaders in their field, each vetted and formally approved by the specialty chief editor.

  • Publishing your article within a Research Topic with other related articles increases its discoverability and visibility, which can lead to more views, downloads, and citations. Research Topics grow dynamically as more published articles are added, causing frequent revisiting, and further visibility.

    As Research Topics are multidisciplinary, they are cross-listed in several fields and section journals – increasing your reach even more and giving you the chance to expand your network and collaborate with researchers in different fields, all focusing on expanding knowledge around the same important topic.

    Our larger Research Topics are also converted into ebooks and receive social media promotion from our digital marketing team.

  • Frontiers offers multiple article types, but it will depend on the field and section journals in which the Research Topic will be featured. The available article types for a Research Topic will appear in the drop-down menu during the submission process.

    Check available article types here 

  • Yes, we would love to hear your ideas for a topic. Most of our Research Topics are community-led and suggested by researchers in the field. Our in-house editorial team will contact you to talk about your idea and whether you’d like to edit the topic. If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. 

    Suggest your topic here 

  • A team of guest editors (called topic editors) lead their Research Topic. This editorial team oversees the entire process, from the initial topic proposal to calls for participation, the peer review, and final publications.

    The team may also include topic coordinators, who help the topic editors send calls for participation, liaise with topic editors on abstracts, and support contributing authors. In some cases, they can also be assigned as reviewers.

  • As a topic editor (TE), you will take the lead on all editorial decisions for the Research Topic, starting with defining its scope. This allows you to curate research around a topic that interests you, bring together different perspectives from leading researchers across different fields and shape the future of your field. 

    You will choose your team of co-editors, curate a list of potential authors, send calls for participation and oversee the peer review process, accepting or recommending rejection for each manuscript submitted.

  • As a topic editor, you're supported at every stage by our in-house team. You will be assigned a single point of contact to help you on both editorial and technical matters. Your topic is managed through our user-friendly online platform, and the peer review process is supported by our industry-first AI review assistant (AIRA).

  • If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. This provides you with valuable editorial experience, improving your ability to critically evaluate research articles and enhancing your understanding of the quality standards and requirements for scientific publishing, as well as the opportunity to discover new research in your field, and expand your professional network.

  • Yes, certificates can be issued on request. We are happy to provide a certificate for your contribution to editing a successful Research Topic.

  • Research Topics thrive on collaboration and their multi-disciplinary approach around emerging, cutting-edge themes, attract leading researchers from all over the world.

  • As a topic editor, you can set the timeline for your Research Topic, and we will work with you at your pace. Typically, Research Topics are online and open for submissions within a few weeks and remain open for participation for 6 – 12 months. Individual articles within a Research Topic are published as soon as they are ready.

    Find out more about our Research Topics

  • Our fee support program ensures that all articles that pass peer review, including those published in Research Topics, can benefit from open access – regardless of the author's field or funding situation.

    Authors and institutions with insufficient funding can apply for a discount on their publishing fees. A fee support application form is available on our website.

  • In line with our mission to promote healthy lives on a healthy planet, we do not provide printed materials. All our articles and ebooks are available under a CC-BY license, so you can share and print copies.

Impact

  • 38kTopic views
  • 24kArticle views
  • 12kArticle downloads
View impact